UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Relapsed/refractory B-cell Malignancies
DRUG: UBX-303061
Number of subjects with Protocol Specified Dose-Limiting Toxicities, Phase 1a and 1b, 28-days|To establish the maximum tolerated dose and/or recommended Phase 1b dose(s), Phase 1a and 1b, Up to End of Treatment (up to 9 months)|Number of subjects with dose interruptions, reductions, and doses administered, Phase 1a and qb, Up to End of Treatment (up to 9 months)
To evaluate the anti-tumor activity of UBX-303061 in the dose levels based on Best overall response, Phase 1a and 1b, Up to End of Treatment (up to 9 months)|To assess genetic markers including but not limited to BTK, PLCG2, MYD88, Phase 1a and 1b, Up to End of Treatment (up to 9 months)|To assess Cmin, Phase 1a and 1b, 28-days|To assess tmax, Phase 1a and 1b, 28-days|To assess AUC, Phase 1a and 1b, 28-days|To assess Cmax, Phase 1a and 1b, 28-days
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.